Pharma Mar Forecast, price target & analysts
Pharma Mar Target price 2025 - Analyst rating & recommendation
Pharma Mar Classifications & Recommendation:
Pharma Mar Price Target
| Target Price | €107.10 |
| Price | €88.60 |
| Potential |
20.88%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Pharma Mar 2026 .
The average Pharma Mar target price is €107.10.
This is
20.88%
register free of charge
€123.90
39.84%
register free of charge
€31.82
64.09%
register free of charge
|
|
| A rating was issued by 11 analysts: 7 Analysts recommend Pharma Mar to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharma Mar stock has an average upside potential 2026 of
20.88%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 174.86 | 202.04 |
| 10.57% | 15.54% | |
| EBITDA Margin | 6.10% | 31.66% |
| 2,397.70% | 418.84% | |
| Net Margin | 14.94% | 29.35% |
| 1,973.07% | 96.41% |
8 Analysts have issued a sales forecast Pharma Mar 2025 . The average Pharma Mar sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Pharma Mar EBITDA forecast 2025. The average Pharma Mar EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Pharma Mar Analysts have issued a net profit forecast 2025. The average Pharma Mar net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 1.49 | 3.37 |
| 2,383.33% | 126.17% | |
| P/E | 26.26 | |
| EV/Sales | 7.18 |
8 Analysts have issued a Pharma Mar forecast for earnings per share. The average Pharma Mar EPS is
This results in the following potential growth metrics and future valuations:
Current Pharma Mar Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| CAIXABANK BPI |
Locked
➜
Locked
|
Locked | Jun 29 2025 |
| ALANTRA EQUITIES |
Locked
➜
Locked
|
Locked | Jun 09 2025 |
| CHARDAN CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | May 26 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | May 22 2025 |
| NEEDHAM & COMPANY INC. |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| ALANTRA EQUITIES |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
CAIXABANK BPI:
Locked
➜
Locked
|
Jun 29 2025 |
|
Locked
ALANTRA EQUITIES:
Locked
➜
Locked
|
Jun 09 2025 |
|
Locked
CHARDAN CAPITAL MARKETS:
Locked
➜
Locked
|
May 26 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
May 22 2025 |
|
Locked
NEEDHAM & COMPANY INC.:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
ALANTRA EQUITIES:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Apr 02 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
